Astragaloside IV suppresses transforming growth factor-β1-induced epithelial-mesenchymal transition through inhibition of Wnt/β-catenin pathway in glioma U251 cells

Bioscience, Biotechnology, and Biochemistry
Jinming HanLeijie Zhou

Abstract

Astragaloside IV (AS#IV) has previously demonstrated antitumoractivity. We investigated the effect and mechanisms of AS#IV in relation to epithelial-mesenchymal transition (EMT), viainterference with the Wnt/β-catenin signaling pathway in gliomaU251 cells. Induction of glioma U251 cells by transforming growthfactor (TGF)#β1 activated EMT, including switching E#cadherin toN-cadherin and altering the expression of Wnt/β-catenin signalingpathway components such as vimentin, β-catenin, and cyclin-D1.AS-IV inhibited the viability, invasion, and migration of TGF-β1-induced glioma U251 cells. AS-IV also interfered with the TGF#β1-induced Wnt/β-catenin signaling pathway in glioma U251 cells.These findings indicate that AS#IV prohibits TGF#β1-induced EMTby disrupting the Wnt/β-catenin pathway in glioma U251 cells. AS#IV may thus be a potential candidate agent for treating glioma andother central nervous system tumors.

References

Jun 20, 2000·Trends in Genetics : TIG·M KühlR T Moon
Sep 17, 2004·Nature Reviews. Genetics·Randall T MoonAjamete Kaykas
Feb 3, 2005·Acta Neuropathologica·Hiroko Ohgaki, Paul Kleihues
May 26, 2006·Nature·Gerhard Christofori
Feb 20, 2007·Current Opinion in Cell Biology·Riccardo Fodde, Thomas Brabletz
Mar 6, 2007·Expert Opinion on Drug Delivery·Adam N Mamelak, Douglas B Jacoby
Jun 15, 2007·Pathology·Marcello GuarinoGianmario Ballabio
Jul 17, 2007·International Journal of Cancer. Journal International Du Cancer·Falk HlubekThomas Kirchner
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anastasia MuratMonika E Hegi
Jun 3, 2009·The Journal of Clinical Investigation·Raghu Kalluri, Robert A Weinberg
May 24, 2011·Oral Oncology·Xinhua Liang
Mar 29, 2012·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kailiang ZhangChunsheng Kang
Jun 12, 2012·Cell·Hans Clevers, Roel Nusse
Jun 14, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Fu-Lun LiBin Li
Jun 20, 2012·Nature Reviews. Urology·Robert M Kypta, Jonathan Waxman
Dec 22, 2012·Nature Reviews. Cancer·Jamie N Anastas, Randall T Moon
Jan 16, 2013·Current Medicinal Chemistry·X ZhangS J Hu
Sep 13, 2013·Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan·Shuang RenPing Liu
Aug 28, 2016·Fundamental & Clinical Pharmacology·Lei LiMenbayaer Tu
Jun 1, 2017·Medical Oncology·Elena Prieto-GarcíaM Teresa Agulló-Ortuño
Jun 3, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·C BalañáM Benavides

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.